• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Diagnostic tools
      • Research team
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

About AMS

Men and women develop similar complaints while aging

The AMS was developed in response to the lack of standardized scales to measure the severity of aging-symptoms in men, and their impact on quality of life.  Many men experience age-related symptoms similar to those traditionally ascribed to women.  Experiences include impaired memory, lack of concentration, nervousness, depression, insomnia, periodic sweating or hot flushes, bone & joint complaints and reduction of muscle mass. Despite Werner 1 reporting the similarity of male and female complaints as early as the 1940s, age-related complaints in men have only recently been seen in the context of hormonal involution. The debate about male climacteric, as well as its compatibility with the female menopause, continues. 234

Sensations of sweating occurring suddenly and unexpectedly, particularly at night (hot flushes) seem to be common in men and women. The AMS is based on the hypothesis that episodes of sweating might be an important symptom of the changes occurring during aging for both sexes. Moreover, the development of a diagnostic instrument that assesses health-related changes of quality of life (HRQoL) in men may be beneficial for discussions on potential treatment modalities.

Idenfification of Relevant Items

Key objectives

  • To measure health-related quality of life (QoL) or severity of complaints in aging males
  • To measure changes over time and across different cultures (AMS scale available in 29 languages)
  • To measure changes before/ after treatment of androgen deficiency
  • To measure in a standardized way

1. Werner AA. The male climacteric: report of 273 cases. JAMA 1946; 132:188-94.

2. Bauer J. The male climacteric – a misnomer. JAMA 1944; 126: 914-18.

3. Degenhardt A. Wechseljahre beim Mann, gibt es sie? In: Fischer S, Streb-Lieder & Vogt, eds. Wechseljahre für Fortgeschrittene. Frankfurt: Verlag für akademische Schriften. 1995: 104-18.

4. McKinlay JB, Longscope CH, Gray A. The questionable phys. and epidemiologic basis for a male climac-teric syndrome: preliminary results from the Massachusetts Male Aging Study. Maturitas 1989; 11:103-5.

sidebar

Aging Male Symptoms Scale

  • About AMS
  • Self-assessment
  • Languages
  • Development
  • Psychometric Characteristics
  • Correlation with other scales
  • AMS – properties as an outcome measure
  • AMS – properties as a screening tool
  • AMS Publications

To All Diagnostic Tools

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2023 ZEG Berlin

Impressum

Website by Laura Yeffeth.